INHX’s INX-189 is very similar to IDIX’s IDX184 in structure and MoA; both are prodrugs of a monophosphate nucleotide analog of guanosine. This is the short write-up on INX-189 from INHX’s website:
The key distinction between the IDX184 and INX-189 programs is timing: INX-189 has not yet entered phase-1, and hence IDX184 is further advanced by about two years. INX-189 is about even in timing with VRUS’ PSI-938, another drug with the same general structure (#msg-39322313).
Market Data 
Markets 
AI
